SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-127019
Filing Date
2024-11-14
Accepted
2024-11-14 16:03:30
Documents
67
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q alrn-20240930.htm   iXBRL 10-Q 1594091
2 EX-31.1 alrn-ex31_1.htm EX-31.1 16507
3 EX-31.2 alrn-ex31_2.htm EX-31.2 16728
4 EX-32.1 alrn-ex32_1.htm EX-32.1 8023
5 EX-32.2 alrn-ex32_2.htm EX-32.2 8014
  Complete submission text file 0000950170-24-127019.txt   7009688

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alrn-20240930.xsd EX-101.SCH 1124026
69 EXTRACTED XBRL INSTANCE DOCUMENT alrn-20240930_htm.xml XML 985923
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 134196017 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38130 | Film No.: 241461671
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)